FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Keeps Hold Rating On Shares Of Idexx Laboratories, Inc.

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target to $612 from $620, based on 37.3x our 2027 EPS estimate, below IDXX's historical forward P/E averages. We slightly raise our 2026 EPS view to $14.70 from 14.67. We keep our 2027 view at $16.42. IDXX reported a solid Q1, exceeding expectations, with revenue of $1.141B (+11% Y/Y organic) due to strong performance in its Companion Animal Group Diagnostics recurring revenue. However, we see IDXX facing risks in the near term stemming from macroeconomic pressures on consumers that are causing a decline in discretionary wellness-related veterinary visits. This trend poses a financial risk, as IDXX full-year guidance assumes a 1.5% decline in U.S. clinical visits; thus, a further worsening of the economic environment could lead to steeper declines and challenge revenue targets. Additionally, IDXX flagged a minor supply chain disruption in the Middle East, which, while contained, underscores the potential for broader operational risks within global business activities.

Related Articles

Research

Research Alert: Grab Achieves $120m Q1 Profit With 24% Revenue Growth, Reaffirms Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Grab posted strong Q1 2026 results with revenue of $955M (+24% Y/Y) and net profit of $120M vs. $10M in the prior year, marking the second consecutive quarter of GAAP profitability. Adjusted EBITDA surged 46% Y/Y to $154M, with margin expanding 250 bps to 16.2%, demonstrating operating leverage in all segments including Mobility GMV growth of 23% and Deliveries GMV expansion of 25%. Key strategic milestones include securing Singapore's inaugural cross-border ride-hail license for the Singapore-Johor corridor and announcing its first international expansion through the acquisition of Taiwan's foodpanda. Executing $500M in share repurchases reflects management's confidence. Management maintained full-year 2026 revenue guidance of $4.04B-$4.10B and $700M-$720M in Adjusted EBITDA, which in our view, indicates confidence in sustained momentum. Financial Services revenue grew 43% to $107M with loan portfolio more than doubling to $1.4B, while strong advertising monetization led Deliveries profitability improvements.

$GRAB
Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Alliant Energy Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target by $2 to $75, valuing LNT at 21.5x our next-12-month EPS view. We trim our 2026 EPS view by $0.03 to $3.42 and trim 2027 by $0.02 to $3.68. Rate base growth stemmed from investments in generation, energy storage, and transmission assets, along with higher allowance for funds used during construction. LNT signed an additional ~370 MW electric service agreement in Iowa, bringing total contracted data center demand to ~3.4 GW (up from 3 GW previously), with the potential to add another 2-4 GW depending on ongoing negotiations. LNT now has five fully executed data center agreements, with three projects under active construction. In our opinion, the strategic focus on capacity-only electric service agreements, supported by flexible generation (simple cycle natural gas and battery storage), aligns capital deployment with revenue growth while preserving optionality for future energy needs. We think EPS and dividend growth (2025-2028) is attractive at 7.6% and 6.1%, respectively.

$LNT
Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Builders Firstsource, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $85 from $125, based on a 2027 P/E of 13.1x, a premium to the stock's 10-year average forward P/E of 12.1x, justified by cyclical trough market conditions. We lower our adjusted EPS estimates to $4.10 from $6.69 for 2026 and to $6.50 from $8.01 for 2027. BLDR posted Q1 2026 adjusted EPS of $0.27 vs. $1.51 (-82% Y/Y), well short of the $0.37 consensus. BLDR's Q1 sales fell 11% to $3.29B ($130M ahead of consensus), but gross margin contracted 220 bps to 28.3%. BLDR said it now expects 2026 net sales of $14.6B-$15.6B and adjusted EBITDA of $1.1B-$1.5B, versus prior expectations of $14.8B-$15.8B and $1.3B-$1.7B, respectively. Management said it remains focused on factors within its control, including serving customers, expanding its differentiated portfolio of value-added solutions, and leveraging technology to accelerate growth and drive operational excellence. We think BLDR's Q1 results underscore challenges the company faces from a weaker housing market.

$BLDR